Agilent Technologies (NYSE:A) Raised to Buy at Wall Street Zen

Agilent Technologies (NYSE:A) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Friday.

A number of other research firms have also weighed in on A. Wells Fargo & Company upped their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. Evercore ISI lowered their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research note on Thursday, August 28th. Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Finally, Barclays upped their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $142.17.

Agilent Technologies Stock Up 2.3%

Shares of A opened at $141.91 on Friday. The firm has a market capitalization of $40.23 billion, a P/E ratio of 33.31, a P/E/G ratio of 4.62 and a beta of 1.26. Agilent Technologies has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a fifty day moving average price of $122.80 and a 200-day moving average price of $116.37.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts expect that Agilent Technologies will post 5.58 earnings per share for the current year.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after buying an additional 4,362 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. grew its stake in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after purchasing an additional 3,040 shares during the period. D.A. Davidson & CO. grew its stake in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. grew its stake in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after purchasing an additional 54,302 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.